ClinVar Miner

Submissions for variant NM_000251.3(MSH2):c.688G>C (p.Ala230Pro)

dbSNP: rs1672818590
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001222948 SCV001395073 uncertain significance Hereditary nonpolyposis colorectal neoplasms 2021-10-13 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with MSH2-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with proline at codon 230 of the MSH2 protein (p.Ala230Pro). The alanine residue is weakly conserved and there is a small physicochemical difference between alanine and proline.
Ambry Genetics RCV002366004 SCV002666162 uncertain significance Hereditary cancer-predisposing syndrome 2015-09-17 criteria provided, single submitter clinical testing The p.A230P variant (also known as c.688G>C), located in coding exon 4 of the MSH2 gene, results from a G to C substitution at nucleotide position 688. The alanine at codon 230 is replaced by proline, an amino acid with highly similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.002% (greater than 65000 alleles tested) in our clinical cohort. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of p.A230P remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.